Literature DB >> 16210565

Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation.

Xiaohua Jiang1, Fan Yang, Hongmei Tan, Dan Liao, Robert M Bryan, Jaspreet K Randhawa, Rolando E Rumbaut, William Durante, Andrew I Schafer, Xiaofeng Yang, Hong Wang.   

Abstract

OBJECTIVE: A risk factor for cardiovascular disease, hyperhomocystinemia (HHcy), is associated with endothelial dysfunction. In this study, we examined the mechanistic role of HHcy in endothelial dysfunction. METHODS AND
RESULTS: Through the use of 2 functional models, aortic rings and intravital video microscopy of the cremaster, we found that arterial relaxation in response to the endothelium-dependent vessel relaxant, acetylcholine or the nitric oxide synthase (NOS) activator (A23187), was significantly impaired in cystathionine beta-synthase null (CBS(-/-)) mice. However, the vascular smooth muscle cell (VSMC) response to the nitric oxide (NO) donor (SNAP) was preserved in CBS(-/-) mice. In addition, superoxide dismutase and catalase failed to restore endothelium-dependent vasodilatation. Endothelial nitric oxide synthase (eNOS) activity was significantly reduced in mouse aortic endothelial cells (MAECs) of CBS(-/-) mice, as well as in Hcy-treated mouse and human aortic endothelial cells (HAECs). Hcy-mediated eNOS inhibition--which was not rescued by adenoviral transduction of superoxide dismutase and glutathione peroxidase, or by tetrahydrobiopterin, sepiapterin, and arginine supplementations in MAEC--was associated with decreased protein expression and increased threonine 495 phosphorylation of eNOS in HAECs. Ultimately, a protein kinase C (PKC) inhibitor, GF109203X (GFX), reversed Hcy-mediated eNOS inactivation and threonine 495 phosphorylation in HAECs.
CONCLUSIONS: These data suggest that HHcy impairs endothelial function and eNOS activity, primarily through PKC activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210565      PMCID: PMC4400833          DOI: 10.1161/01.ATV.0000189559.87328.e4

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  30 in total

Review 1.  Oxidative stress, antioxidants, and endothelial function.

Authors:  Eberhard Schulz; Elad Anter; John F Keaney
Journal:  Curr Med Chem       Date:  2004-05       Impact factor: 4.530

2.  Effects of homocysteine on murine splenic B lymphocyte proliferation and its signal transduction mechanism.

Authors:  Q Zhang; X Zeng; J Guo; X Wang
Journal:  Cardiovasc Res       Date:  2001-11       Impact factor: 10.787

Review 3.  Hyperhomocysteinemia and atherosclerosis.

Authors:  Fan Yang; Hong-Mei Tan; Hong Wang
Journal:  Sheng Li Xue Bao       Date:  2005-04-25

4.  Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice.

Authors:  S Dayal; T Bottiglieri; E Arning; N Maeda; M R Malinow; C D Sigmund; D D Heistad; F M Faraci; S R Lentz
Journal:  Circ Res       Date:  2001-06-08       Impact factor: 17.367

5.  Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules.

Authors:  Guoping Wang; Connie W H Woo; Fion L Sung; Yaw L Siow; Karmin O
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-11-01       Impact factor: 8.311

6.  Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice.

Authors:  W Shi; M E Haberland; M L Jien; D M Shih; A J Lusis
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

7.  Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine.

Authors:  J C Chambers; P M Ueland; O A Obeid; J Wrigley; H Refsum; J S Kooner
Journal:  Circulation       Date:  2000-11-14       Impact factor: 29.690

8.  Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia.

Authors:  M Watanabe; J Osada; Y Aratani; K Kluckman; R Reddick; M R Malinow; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 9.  Selective protein kinase C inhibitors and their applications.

Authors:  Garry X Shen
Journal:  Curr Drug Targets Cardiovasc Haematol Disord       Date:  2003-12

Review 10.  Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.

Authors:  Rainer H Böger
Journal:  J Nutr       Date:  2004-10       Impact factor: 4.798

View more
  61 in total

Review 1.  Interactions of hyperhomocysteinemia and T cell immunity in causation of hypertension.

Authors:  Sudhakar Veeranki; Siva K Gandhapudi; Suresh C Tyagi
Journal:  Can J Physiol Pharmacol       Date:  2016-04-28       Impact factor: 2.273

Review 2.  Vascular complications of cystathionine β-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research.

Authors:  Richard S Beard; Shawn E Bearden
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-22       Impact factor: 4.733

3.  Inhibition of Caspase-1 Activation in Endothelial Cells Improves Angiogenesis: A NOVEL THERAPEUTIC POTENTIAL FOR ISCHEMIA.

Authors:  Jahaira Lopez-Pastrana; Lucas M Ferrer; Ya-Feng Li; Xinyu Xiong; Hang Xi; Ramon Cueto; Jun Nelson; Xiaojin Sha; Xinyuan Li; Ann L Cannella; Princess I Imoukhuede; Xuebin Qin; Eric T Choi; Hong Wang; Xiao-Feng Yang
Journal:  J Biol Chem       Date:  2015-06-02       Impact factor: 5.157

4.  Cystathionine beta synthase gene dose dependent vascular remodeling in murine model of hyperhomocysteinemia.

Authors:  Neetu Tyagi; Natia Qipshidze; Utpal Sen; Walter Rodriguez; Alexander Ovechkin; Suresh C Tyagi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-09-08

5.  High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts.

Authors:  A Solini; E Santini; M Nannipieri; E Ferrannini
Journal:  Diabetologia       Date:  2006-08-01       Impact factor: 10.122

6.  Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice.

Authors:  Daqing Zhang; Pu Fang; Xiaohua Jiang; Jun Nelson; Jodene K Moore; Warren D Kruger; Remus M Berretta; Steven R Houser; Xiaofeng Yang; Hong Wang
Journal:  Circ Res       Date:  2012-05-24       Impact factor: 17.367

7.  Cellular hypomethylation is associated with impaired nitric oxide production by cultured human endothelial cells.

Authors:  M Barroso; M S Rocha; R Esse; I Gonçalves; A Q Gomes; T Teerlink; C Jakobs; H J Blom; J Loscalzo; I Rivera; I Tavares de Almeida; R Castro
Journal:  Amino Acids       Date:  2011-05-26       Impact factor: 3.520

8.  Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect.

Authors:  Leslie G Cook; Valorie L Chiasson; Cheng Long; Gang-Yi Wu; Brett M Mitchell
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

9.  Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia.

Authors:  Roman N Rodionov; Hayan Dayoub; Cynthia M Lynch; Katina M Wilson; Jeff W Stevens; Daryl J Murry; Masumi Kimoto; Erland Arning; Teodoro Bottiglieri; John P Cooke; Gary L Baumbach; Frank M Faraci; Steven R Lentz
Journal:  Circ Res       Date:  2009-12-17       Impact factor: 17.367

10.  Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.

Authors:  Sanjana Dayal; Roman N Rodionov; Erland Arning; Teodoro Bottiglieri; Masumi Kimoto; Daryl J Murry; John P Cooke; Frank M Faraci; Steven R Lentz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.